All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) metastasis (lung) metastasis (lymph node ) PD-L1 < 1% PD-L1 > 1% stage II stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
breast cancer (BC), anti-PD-(L)1 vs. non active control, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS) (extension)detailed results GeparNuevo, 2019 0.24 [0.03; 2.28]
0.24 [0.03 ; 2.28 ] GeparNuevo, 2019 1 0% 174 NA not evaluable events or deaths (EFS)detailed results KEYNOTE-522, 2020 0.63 [0.43; 0.93]
0.63 [0.43 ; 0.93 ] KEYNOTE-522, 2020 1 0% 1,174 NA not evaluable pCR detailed results GeparNuevo, 2019 1.45 [0.80; 2.63]
KEYNOTE-522, 2020 13.60 [6.77; 27.33]
4.41 [0.49 ; 39.52 ] GeparNuevo, 2019, KEYNOTE-522, 2020 2 96% 776 moderate not evaluable AE (any grade)detailed results KEYNOTE-522, 2020 0.25 [0.01; 4.74]
0.25 [0.01 ; 4.74 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-522, 2020 1.35 [1.01; 1.80]
1.35 [1.01 ; 1.80 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable AE leading to death (grade 5)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable SAE (any grade)detailed results GeparNuevo, 2019 0.88 [0.47; 1.66]
0.88 [0.47 ; 1.66 ] GeparNuevo, 2019 1 0% 174 NA not evaluable TRAE (any grade)detailed results KEYNOTE-522, 2020 0.25 [0.03; 2.00]
0.25 [0.03 ; 2.00 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.26 [0.96; 1.66]
1.26 [0.96 ; 1.66 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-522, 2020 1.50 [0.16; 14.43]
1.50 [0.16 ; 14.43 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-522, 2020 2.16 [1.53; 3.05]
2.16 [1.53 ; 3.05 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 10.08 [0.59; 173.00]
10.08 [0.59 ; 173.00 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.87 [0.36; 2.09]
0.87 [0.36 ; 2.09 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.27 [0.91; 1.77]
1.27 [0.91 ; 1.77 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.40 [0.65; 3.02]
1.40 [0.65 ; 3.02 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 3.51 [0.43; 28.62]
3.51 [0.43 ; 28.62 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 3.51 [0.43; 28.62]
3.51 [0.43 ; 28.62 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.99 [0.09 ; 44.34 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.71 [0.63; 4.67]
1.71 [0.63 ; 4.67 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 2.29 [0.94; 5.58]
2.29 [0.94 ; 5.58 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.13 [0.82; 1.57]
1.13 [0.82 ; 1.57 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 9.06 [0.52; 156.66]
9.06 [0.52 ; 156.66 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.99 [0.09 ; 44.34 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 8.04 [0.46; 140.38]
8.04 [0.46 ; 140.38 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 3.00 [0.15; 59.96]
3.00 [0.15 ; 59.96 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 9.67 [1.29; 72.54]
9.67 [1.29 ; 72.54 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 2.34 [1.13; 4.86]
2.34 [1.13 ; 4.86 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 2.53 [0.86; 7.45]
2.53 [0.86 ; 7.45 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.76 [0.57; 1.03]
0.76 [0.57 ; 1.03 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.99 [0.09 ; 44.34 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 2.64 [1.01; 6.94]
2.64 [1.01 ; 6.94 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 7.03 [0.40; 124.15]
7.03 [0.40 ; 124.15 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.06 [0.82; 1.38]
1.06 [0.82 ; 1.38 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 4.00 [0.21; 75.85]
4.00 [0.21 ; 75.85 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.88 [0.62; 5.72]
1.88 [0.62 ; 5.72 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.20 [0.42; 3.43]
1.20 [0.42 ; 3.43 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.50 [0.16; 14.43]
1.50 [0.16 ; 14.43 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 4.02 [0.50; 32.22]
4.02 [0.50 ; 32.22 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 3.51 [0.43; 28.62]
3.51 [0.43 ; 28.62 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Sarcoidosis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 15.50 [2.11; 114.09]
15.50 [2.11 ; 114.09 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 11.10 [0.65; 189.37]
11.10 [0.65 ; 189.37 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.99 [0.09 ; 44.34 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.51 [0.59; 3.82]
1.51 [0.59 ; 3.82 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results GeparNuevo, 2019 1.79 [0.06; 54.10]
1.79 [0.06 ; 54.10 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Abdominal pain AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Alopecia AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Anaemia AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.12; 6.46]
0.89 [0.12 ; 6.46 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Arthralgia AE (grade 3-4)detailed results GeparNuevo, 2019 1.80 [0.16; 20.23]
1.80 [0.16 ; 20.23 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Back pain AE (grade 3-4)detailed results GeparNuevo, 2019 0.44 [0.01; 13.37]
0.44 [0.01 ; 13.37 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Blood creatinine increased AE (grade 3-4)detailed results GeparNuevo, 2019 0.05 [0.00; 0.89]
0.05 [0.00 ; 0.89 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Constipation AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.05; 14.46]
0.89 [0.05 ; 14.46 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Cough AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Diarrhoea AE (grade 3-4)detailed results GeparNuevo, 2019 5.49 [0.27; 111.35]
5.49 [0.27 ; 111.35 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Dry skin AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Dyspnoea AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Epistaxis AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Fatigue AE (grade 3-4)detailed results GeparNuevo, 2019 0.47 [0.15; 1.45]
0.47 [0.15 ; 1.45 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results GeparNuevo, 2019 1.82 [0.32; 10.20]
1.82 [0.32 ; 10.20 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Headache AE (grade 3-4)detailed results GeparNuevo, 2019 1.79 [0.06; 54.10]
1.79 [0.06 ; 54.10 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Hyperthyroidism AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Hypophysitis AE (grade 3-4)detailed results GeparNuevo, 2019 1.79 [0.06; 54.10]
1.79 [0.06 ; 54.10 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Increase AST AE (grade 3-4)detailed results GeparNuevo, 2019 5.49 [0.27; 111.35]
5.49 [0.27 ; 111.35 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Increased ALT AE (grade 3-4)detailed results GeparNuevo, 2019 1.20 [0.26; 5.51]
1.20 [0.26 ; 5.51 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Injury, poisoning and procedure AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.05; 14.46]
0.89 [0.05 ; 14.46 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Leucopenia AE (grade 3-4)detailed results GeparNuevo, 2019 0.84 [0.45; 1.57]
0.84 [0.45 ; 1.57 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Myalgia AE (grade 3-4)detailed results GeparNuevo, 2019 1.82 [0.32; 10.20]
1.82 [0.32 ; 10.20 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Nausea AE (grade 3-4)detailed results GeparNuevo, 2019 0.06 [0.00; 1.05]
0.06 [0.00 ; 1.05 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Neutropenia AE (grade 3-4)detailed results GeparNuevo, 2019 0.83 [0.45; 1.52]
0.83 [0.45 ; 1.52 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results GeparNuevo, 2019 0.88 [0.33; 2.33]
0.88 [0.33 ; 2.33 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Pneumonitis AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Rash AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.05; 14.46]
0.89 [0.05 ; 14.46 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Stomatitis AE (grade 3-4)detailed results GeparNuevo, 2019 3.62 [0.16; 81.50]
3.62 [0.16 ; 81.50 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results GeparNuevo, 2019 0.44 [0.04; 4.94]
0.44 [0.04 ; 4.94 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Vomiting AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.05; 14.46]
0.89 [0.05 ; 14.46 ] GeparNuevo, 2019 1 0% 174 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 13:54 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563